• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Tulathromycin A

CAS号

217500-96-4

分子式

C41H79N3O12

主要靶点

Antibiotic|Antibacterial

仅限科研使用

Cat No : CM02918

Print datasheet

Synonyms

CP472295|CP-472295|CP 472295|Draxxin|inhibit|Bacterial|cattle|Antibiotic|Antibacterial|ribosome|pneumonia|Inhibitor|leukocytes|托拉菌素 A|swine|Tulathromycin|Tulathromycin A

验证数据展示

  • CAS No.: 217500-96-4

    Tulathromycin A
    CAS#: 217500-96-4

产品信息

CAS号 217500-96-4
分子式 C41H79N3O12
主要靶点 Antibiotic|Antibacterial
主要通路 微生物学|微生物学
分子量 806.08
纯度 99.46%， 此纯度可做参考，具体纯度与批次有关系，可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
别名 CP472295|CP-472295|CP 472295|Draxxin|inhibit|Bacterial|cattle|Antibiotic|Antibacterial|ribosome|pneumonia|Inhibitor|leukocytes|托拉菌素 A|swine|Tulathromycin|Tulathromycin A

靶点活性

Antibacterial:1 microg/ml (MIC90 for Pasteurella multocida)

体内活性

每项研究均随机分配250头小牛接受2.5 mg/kg的tulathromycin治疗，另外250头小牛接受40 mg/kg的florfenicol或10 mg/kg的tilmicosin治疗，治疗开始于牛群抵达育肥场时。小牛按照治疗组别分放在每组有50头小牛的围栏中。治疗组别分别为生理盐水（n=160）以0.02 ml/kg的剂量皮下注射(SC)、tulathromycin（n=20）以2.5 mg/kg的剂量皮下注射以及tilmicosin（n=320）以10 mg/kg的剂量皮下注射。

体外活性

145头小牛接种了两株高致病性的M. bovis菌株（最小抑菌浓度分别为1和>64 μg/ml）。接种后四天，表现出临床BRD症状的小牛通过皮下注射方式，接受了生理盐水或tulathromycin（2.5 mg/kg）治疗。与生理盐水相比，接受tulathromycin治疗的小牛在BRD相关的淘汰率、最高直肠温度和肺部病变评分上显著降低（P < .01）。无论挑战菌株的最小抑菌浓度为1还是>64 μg/ml，tulathromycin在治疗因M. bovis引起的BRD疾病中均显示出高效的疗效。对于Pasteurella multocida（牛源）、Mannheimia (Pasteurella) haemolytica、Pasteurella multocida（猪源）、Actinobacillus pleuropneumoniae以及Histophilus somni（Haemophilus somnus），tulathromycin的MIC90分别为1 μg/ml、2 μg/ml、2 μg/ml、4-16 μg/ml和0.5-4 μg/ml。

溶解度

DMSO:60 mg/mL (74.43 mM)

参考文献

1.Villarino N, et al. Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally withlipopolysaccharide from Escherichia coli. Antimicrob Agents Chemother. 2012 Aug;56(8):4078-4086.
2.Godinho KS, et al. Efficacy of tulathromycin in the treatment of bovine respiratory disease associated with induced Mycoplasma bovis infections in young dairy calves. Vet Ther. 2005 Summer;6(2):96-112.
3.Godinho KS, et al. Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology. Vet Ther. 2005 Summer;6(2):113-21.
4.Rooney KA, et al. Efficacy of tulathromycin compared with tilmicosin and florfenicol for the control of respiratory disease in cattle at high risk of developing bovine respiratory disease. Vet Ther. 2005 Summer;6(2):154-66.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2